Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$11.3B
157M shares
52-week range
$43.20 – $72.62
99% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
P/S (TTM)
9.3
EV / FCF (TTM)
43.2
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
www.bio-techne.comNo one on the platform currently holds TECH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 590,700 | $30.4M |
| Bridgewater Associatesas of 2026-03-31 | 5,977 | $312.4K |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-24 | $0.0800 | 2026-09-04 |
| 2026-05-18 | $0.0800 | 2026-05-29 |
| 2026-02-13 | $0.0800 | 2026-02-27 |
| 2025-11-17 | $0.0800 | 2025-11-28 |
| 2025-08-18 | $0.0800 | 2025-08-29 |
| 2025-05-19 | $0.0800 | 2025-05-30 |
| 2025-02-14 | $0.0800 | 2025-02-28 |
| 2024-11-08 | $0.0800 | 2024-11-22 |
| 2024-08-19 | $0.0800 | 2024-08-30 |
| 2024-05-10 | $0.0800 | 2024-05-24 |
No one on the platform has traded TECH yet.
| 2024-02-09 | $0.0800 | 2024-02-26 |
| 2023-11-09 | $0.0800 | 2023-11-24 |
| Execution date | Ratio |
|---|---|
| 2022-11-30 | 4-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.9% | 9.1% | 9.0% | — | — | — |
| Rev. Growth % | -0.4% | 5.5% | ||||
| Profit Margin % | 15.0% | 17.0% | 17.8% | |||
| Free Cash Flow Margin % | 21.7% | 21.5% | 22.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +0.5% on the P/E track.
At today's price, your expected annual return is +5.8% on the P/E track.
At today's price, your expected annual return is +11.0% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.3B | +5.1% | $2.06 | $1.95–$2.17 | 35.2× | 8 |
| 2028 | $1.4B | +9.7% | $2.34 | $2.25–$2.43 | 30.9× | 5 |
| 2029 | $1.6B | +13.2% | $2.68 | $2.59–$2.82 | 27.0× | 1 |
| 2030 | $1.7B | +9.0% | $2.46 | $2.38–$2.59 | 29.4× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.52 | $0.52 | +0.2% |
| 2026-05-06 | $0.55 | $0.53 | -3.6% |
| 2026-02-04 | $0.43 | $0.46 | +7.0% |
| 2025-11-05 | $0.42 | $0.42 | -0.3% |
| 2025-08-06 | $0.50 | $0.53 | +6.0% |
| 2025-05-07 | $0.51 | $0.56 | +9.8% |
| 2025-02-05 | $0.39 | $0.42 | +7.7% |
| 2024-10-30 | $0.38 |
| $0.42 |
| +10.5% |
| $14.1B |
| — |
| JAZZJazz Pharmaceuticals plc | $245.87 | +0.03% | $15.4B | — |
| MDGLMadrigal Pharmaceuticals, Inc. | $540.06 | +1.04% | $12.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
🚨 $AIMN AimwellBio just secured a patented Behavioral AI portfolio backed by work involving Oxford Science and a Sanofi pilot. This could be a major step in bringing AI-driven behavioral insights into real-world healthcare applications. 🧠🤖 Patented IP + AI + pharmaceutical validation = a setup worth watching closely. $AIMN $AI $BIOTECH $TECH #AIMN #AI #Biotech #BehavioralAI #Healthcare
View on StockTwits ↗
$TECH reported 0.52 EPS and 321.19 revenue for Q4. http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_content=TECH&utm
View on StockTwits ↗
$TECH undiscovered breakout with 677 watchers
View on StockTwits ↗Wall St is expecting 0.44 EPS for $TECH Q1 [Reporting 11/03 BMO] http://www.estimize.com/intro/tech?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
$MICC $TECH $BPOP $WTRG $JKHY MICC remains execution-driven, Bio-Techne benefits from life sciences demand, Popular strengthens Puerto Rican banking, Essential Utilities provides regulated water services, and Jack Henry leads community banking software.
View on StockTwits ↗
Stock market today: Nasdaq surges, Dow and S&P 500 trade at record highs amid US-Iran optimism, tech rally stocks boosted the major indexes on Tuesday morning as markets eyed Middle East talks and earnings rolled in, with the arrival of $TECH SpaceX's (SPCX) earnings after the bell in focus.
View on StockTwits ↗
$ALT $APGE $FOLD $TECH $TERN So, in your Tern chart, short interest increased over a 6 month period by 1.5-2.5 times its SI 6 months earlier. Wow. Then hit Not fairy tale gobbledygook. Legitimate. Market. Analysis. 👏👏👏👏👏👏👏👏👏👏
View on StockTwits ↗
$ALT $APGE $FOLD $TECH Short interest of $TERN kept growing and were running into Merck s BO- Offer on March 25 😉👇
View on StockTwits ↗$ALT $APGE $FOLD $TECH Trade, interesting thoughts on WHY we see rising short interest and an increase in Bashers ahead of BO news…
View on StockTwits ↗$ALT $APGE $FOLD $TECH What I can tell you without any more dd, Dilution is not uncommon before a deal. Basta!
View on StockTwits ↗
$ALT $TECH $APGE $FOLD interesting. Have you matched it with the available shares of those companies? Maybe it's just that they diluted too and mire available shares meant more shorting? Or dilution means upcoming buyout?
View on StockTwits ↗$ALT $APGE $FOLD $TECH Trade, that’s a HELLUVA find. Great job man….🙏🙏😎😎
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.